Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Search results (19)

« Back to Publications

Spatial fibroblast niches define Crohn's fistulae.

McGregor C. et al, (2026), Nature, 649, 703 - 712

Correction: Spatial fibroblast niches define Crohn's fistulae.

McGregor C. et al, (2025), Nature, 648

Development and validation of peripheral blood DNA methylation signatures to predict response to biological therapy in adults with Crohn's disease (EPIC-CD): an epigenome-wide association study.

Joustra VW. et al, (2025), Lancet Gastroenterol Hepatol, 10, 818 - 830

DECREASED CD8A AND CD8B EXPRESSING BLOOD T CELL POPULATIONS MAY PREDICT ADALIMUMAB AND INFLIXIMAB RESPONSE FAILURE IN CROHN'S DISEASE PATIENTS

Mol F. et al, (2025), GASTROENTEROLOGY, 169

Tracking in situ checkpoint inhibitor-bound target T cells in patients with checkpoint-induced colitis.

Gupta T. et al, (2024), Cancer Cell, 42, 797 - 814.e15

HIGHER PREDICTIVE POWER OF EPIGENETIC SIGNATURES FOR RESPONSE TO VEDOLIZUMAB AND USTEKINUMAB IN ANTI-TNF NAIVE PATIENTS WITH ACTIVE CROHN'

van Zon S. et al, (2024), GASTROENTEROLOGY, 166, S1413 - S1413

SPATIALLY RESOLVED INSIGHTS INTO FISTULATING CROHN'S DISEASE PATHOGENESIS: UNVEILING MOLECULAR HETEROGENEITY

McGregor C. et al, (2024), GASTROENTEROLOGY, 166, S47 - S47

Geography Influences Susceptibility to SARS-CoV-2 Serological Response in Patients With Inflammatory Bowel Disease: Multinational Analysis From the ICARUS-IBD Consortium.

Wong S-Y. et al, (2023), Inflamm Bowel Dis, 29, 1693 - 1705

Early management of acute severe UC in the biologics era: development and international validation of a prognostic clinical index to predict steroid response.

Adams A. et al, (2023), Gut, 72, 433 - 442

Pathogenesis of Fistulating Crohn's Disease: A Review.

McGregor CGC. et al, (2023), Cell Mol Gastroenterol Hepatol, 15, 1 - 11

EPIGENOME-WIDE PERIPHERAL BLOOD DNA METHYLATION PROFILES ACCURATELY PREDICT ENDOSCOPIC- AND CLINICAL RESPONSE AND REMAIN HIGHLY STABLE DURING INDUCTION AND MAINTENANCE TREATMENT WITH ADALIMUMAB, VEDOLIZUMAB AND USTEKINUMAB IN CROHN'S DISEASE PATIENTS

Joustra V. et al, (2023), GASTROENTEROLOGY, 164, S101 - S101

HIGHLY STABLE EPIGENOME-WIDE PERIPHERAL BLOOD DNA METHYLATION SIGNATURES ACCURATELY PREDICT RESPONSE TO ADALIMUMAB, VEDOLIZUMAB AND USTEKINUMAB IN CROHN'S DISEASE PATIENTS

Joustra V. et al, (2023), GUT, 72, A36 - A38

Combination therapy of infliximab and thiopurines, but not monotherapy with infliximab or vedolizumab, is associated with attenuated IgA and neutralisation responses to SARS-CoV-2 in inflammatory bowel disease.

Wellens J. et al, (2022), Gut, 71, 1919 - 1922

Maintenance therapy with infliximab or vedolizumab in IBD is not associated with increased SARS-CoV-2 seroprevalence: UK experience in the 2020 pandemic.

McGregor CG. et al, (2021), Gut, 70, 2398 - 2400

Combination therapy of infliximab and thiopurines, but not monotherapy with infliximab or vedolizumab, is associated with attenuated IgA and neutralisation responses to SARS-CoV-2 in inflammatory bowel disease

Wellens J. et al, (2021)

Load More